Cervical cancer patients' vaginal microbiome and metabolites: research progress and clinical applications
Frontiers in Microbiology · 14.08.2026 · 17
DOI: 10.3389/fmicb.2026.1891111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 14.08.2026. Verfasst von Qian Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
As the fourth most common malignancy among women globally, cervical cancer is intimately linked to persistent high-risk human papillomavirus (HPV) infection; however, HPV infection is not the sole pathogenic factor. Recent studies have revealed that the composition, dynamics, and metabolic products of the vaginal microbiota play pivotal roles in the occurrence, progression, diagnosis, and treatment of cervical cancer. This article offers a comprehensive narrative review of foundational research on the vaginal microbiome in cervical cancer patients, correlations with metabolites, epidemiological characteristics, diagnostic applications, therapeutic strategies, and ongoing controversies and challenges. Basic research demonstrates that increased vaginal microbial diversity and reduced Lactobacillus abundance are associated with cervical cancer progression, wherein pathogenic bacteria such as Fusobacterium spp. and Sneathia spp. have been associated with tumorigenesis through immunosuppression and inflammatory mechanisms. Metabolites like 3-hydroxybutyrate and sphingolipids show potential as diagnostic biomarkers and therapeutic targets. Epidemiological studies reveal associations between variations in the vaginal microbiota across different populations (e.g., African, Latina) and cervical cancer risk. In diagnostics, detection methods based on the vaginal microbiome can enhance early screening efficiency, with novel sequencing technologies combined with artificial intelligence demonstrating promising application prospects. Therapeutically, interventions such as probiotics and microbiota modulation may improve patient outcomes. Nonetheless, current research faces challenges, including an unclear causal relationship between the microbiota and HPV infection and a lack of standardization in detection techniques. Future endeavors necessitate multi-omics integration, large-scale longitudinal studies, and precise intervention strategies to facilitate the clinical translation of vaginal microbiome research into cervical cancer prevention and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China.
- Dazhou Vocational and Technical College, Dahzou, Sichuan, China.
- Department of Obstetrics and Gynecology, Dazhou Central Hospital, Dahzou, Sichuan, China.
- Department of Pediatrics, Dazhou Hospital of Integrated Chinese and Western Medicine, Dahzou, Sichuan, China.
- School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Cardiology, Dazhou Central Hospital, Dazhou, Sichuan, China.
Zitieren
APA
Huang, Q., Zhang, L. Y., Shu, H. L., Chen, N., Li, R. H., Jiang, F. X., Li, G. M., Pu, M., Zhang, Q., Gao, Y. L., & Chu, Y. P. (2026). Cervical cancer patients' vaginal microbiome and metabolites: research progress and clinical applications. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1891111
Vancouver
Huang Q, Zhang LY, Shu HL, Chen N, Li RH, Jiang FX, et al. Cervical cancer patients' vaginal microbiome and metabolites: research progress and clinical applications. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1891111
BibTeX
@article{Huang2026,
author = {Huang, Qian and Zhang, Li Yi and Shu, Hui Lin and Chen, Na and Li, Rong Hua and Jiang, Feng Xi and Li, Guang Ming and Pu, Mei and Zhang, Qian and Gao, Yu Lian and Chu, Yan Peng},
title = {Cervical cancer patients' vaginal microbiome and metabolites: research progress and clinical applications},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1891111}
}
EUVIMED